

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 January 2025 (02.01.2025)



(10) International Publication Number
WO 2025/003471 A1

(51) International Patent Classification:

A61K 38/22 (2006.01) A61P 3/04 (2006.01)
A61K 38/26 (2006.01) A61P 3/06 (2006.01)
C07K 14/575 (2006.01) A61P 3/10 (2006.01)
C07K 14/605 (2006.01) A61P 9/10 (2006.01)
A61P 3/00 (2006.01)

(21) International Application Number:

PCT/EP2024/068365

(22) International Filing Date:

28 June 2024 (28.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23182749.4 30 June 2023 (30.06.2023) EP
23203438.9 13 October 2023 (13.10.2023) EP

(71) Applicant: ZEALAND PHARMA A/S [DK/DK]; Syd-
marken 11, 2860 Soborg (DK).

(72) Inventor: VESTERGAARD, Bill; c/o Zealand Pharma A/
S, Sydmarken 11, 2860 Soborg (DK).

(74) Agent: MILTON, Tamara; D Young & Co LLP, 3 Noble
Street, London EC2V 7BQ (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMBINATION THERAPY

(57) Abstract: The present invention relates to use of an amylin analogue and a dual agonist of the gastric inhibitory polypeptide receptor (GIPR) and the glucagon-like peptide- 1 receptor (GLP-1R) to regulate body weight and to treat or prevent obesity and related conditions.

WO 2025/003471 A1